The report covers:
“Improved imaging capabilities, being able to see the product, why you are doing embolization or see where it went after the embolization on cross-sectional imaging as a confirmation to ensure this is where we delivered our embolics. I think that will be a major change and then additionally different sizes of products that have demonstrated benefit, and if it is better to use 300-500 microns or less you know that has still not being answered yet completely.”
– Interventional Radiologist, Tumor Embolization US
Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such Fluidx Medical’s GPX embolic device’s repeated success in treating complex tumors including a recent case for renal tumor at Christchurch hospital in New Zealand; GPX embolic device being under development, not having marketing clearance or approval in any market at this time and being available for investigational use only in New Zealand are covered in the report.
What’s in it for you?